|
Product Details:
Payment & Shipping Terms:
|
| CAS: | 341031-54-7 | Product Name: | Sunitinib Malate |
|---|---|---|---|
| Type: | Anti Tumor Drugs | Appearance: | White To Yellow Powder |
| Usage: | Anti Cancer | Alias: | SU 011248 |
| Assay: | 99% | Key Words: | Sunitinib Malate |
| High Light: | pharm raw material,raw steroid powders,CAS 341031-54-7 Pharmaceutical Raw Material |
||
99%min Small Molecular Sunitinib Malate (CAS No.: 341031-54-7)
Description:
Name: 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
Superlist Name: Sunitinib
CAS No.: 557795-19-4
Specification: 99%
Formula: C22H27FN4O2
Molecular Weight: 398.47
Density: 1.23 g/cm3
Melting Point: 189-191 °C
Boiling Point: 572.136 °C at 760 mmHg
Flash Point: 299.818 °C
Appearance: white to yellow powder
Application
Sunitinib malate, also called sunitinib, is a novel, oral, multi-targeted , small molecule oxindole tyrosine kinase inhibitor which inhibits multiple receptor tyrosine kinases including c-KIT, FLT3 kinase, colony-stimulating factor 1 receptor and RET kinase. The IC50 of sunitinib is approximately 10-20 ng/ml to NB cell lines, which is within the clinically relevant human trough serum concentration (50-100 ng/ml).
Receptor tyrosine kinases activated a number of different intracellular signaling pathways.
In neuroblastoma (NB) cell lines, SKN-BE (2), NUB-7, SH-SY5Y and LAN-5, sunitinib significantly inhibited cell proliferation after a treatment for 48 hours, in a concentration-dependent manner.
Treatment with 20, 30 or 40 mg/kg of sunitinib made NOD/SCID mice inoculated with xenograft tumor cells show significant reduction (P <0.05) in primary tumor growth (%T/C: 49% for SK-N-BE (2) and 55% for NB12 tumor, T/C: average treated tumor mass/average control tumor mass). Treatment with different doses of sunitinib (20, 30 or 40 mg/kg) for 14 days resulted in a dramatic decrease in the numbers and size of metastatic sites and a significant difference in liver weight in mice injected intravaneously with 106 SK-N-BE(2) cells for 7 days compared with the control group.
COA
Item of analysis |
Standard | Result of analysis | |
| Description | White to pale yellow powder | Conforms | |
| Melting piont | 215.0-227.0ºc | 219.0-220.0ºc | |
| Identification | A:IR | Conresponding to reference spectrum | Conresponding to reference spectrum |
| B :HPLC | Conresponding to reference rt | Conresponding to reference rt | |
| Loss on drying | ≤0.5% | 0.31% | |
| Residual on lgnition | ≤0.5% | 0.19% | |
| Residual solvent | Pyridine | ≤4000ppm | ND |
| DMF | ≤3000ppm | ND | |
| Chloroform | ≤4000ppm | ND | |
| Ordinary impurities | Total impurities≤2.0% | 0.30% | |
| Assay | 98.0%~101.0% | 99.7% | |
Other Small molecular API:
| AZD9291 | 1421373-65-0 |
| E7080 | 417716-92-8 |
| Afatinib diMaleate | 439081-18-2 |
| XL184 S-MALATE | 1140909-48-3 |
| Crizotinib | 877399-52-5 |
| Axitinib | 319460-85-0 |
| WZ4002 | 1213269-23-8 |
| Vandetanib | 443913-73-3 |
| Sunitinib | 557795-19-4 |
| Regorafenib | 755037-03-7 |
| Imatinib | 152459-95-5 |
99%min Small Molecular Sunitinib Malate (CAS No.: 341031-54-7)
Contact Person: Mr. Bruce Lee
Tel: +8618874586545
Fax: 86-27-8321-4688
